What is Vitamin D3 ?
Vitamin D3 (Cholecalciferol) is the form Vitamin D produced by the body after exposure to sunlight.
Common vegetarian Vitamin D supplements are Vitamin D2 (Ergocalciferol),which is a derivative of
ergosterol and is not produced by land plants or vertebrates.The healthy debate continues regarding
whether D2 offers equivalent efficacy to D3 in the body, with the majority of the scientific community
suggesting Vitamin D3 is superior.Having reviewed a vast amount of published research, our conclusion
is that vitamin D3 (Cholecalciferol) is the best form of Vitamin D for the body.
Our exclusive vegan Vitamin D3 (Cholecalciferol) comes from a special, organic plant source called a Lichen. Lichens are small unique plant species consisting of a symbiotic association of a fungus with an algae. This gives them unique attributes such as surviving in extreme climates and having the ability to grow and accumulate meaningful levels of useful nutrients, including Vitamin D3!
There are many different species of Lichen, and we work with a carefully selected strain we have proved contains Vitamin D3. This makes the basis for the perfect Vitamin D supplementation. This truly is vegan and vegetarian Vitamin D3 - an alternative to animal derived supplements such as cod liver oil for those following a vegan diet or a vegetarian diet.
What is K2 (mk-7) ?
Vitamin K2 MK-7 is poised for widespread consumer uptake in the immediate future due to its superior bone and heart health benefits. Kappa Bioscience has the vision to deliver vitamin K2 to the mass market, making it accessible for everybody, everywhere. Positioned for unlimited-scale market opportunities, the company offers customers a strong partner in the development of new market growth with K2VITAL.
The origin of K2VITAL dates back to 2006, when Norwegian researcher Dr Inger Reidun Aukrust, together with her team, discovered a process to produce all-trans vitamin K2 MK-7, using natural compounds such as geraniol and farnesol in a strictly controlled synthesis process.
The significance of the process for all-trans vitamin K2 MK-7 has been recognised and patented. For vitamin K, two stereo-chemical versions can exist: cis and trans forms of the molecule. The cis form remains biologically inactive, while the trans form has a full biological potential. Commercially available vitamin K2 products may contain both forms.
Why we need vitamin K2 MK-7
The effect of vitamin K2 MK-7 in your body is highly different from the effect of vitamin K1 even though the function of K as K1 or K2 is principally the same. This is because vitamin K1 has a very short half-life and rapid excretion, and is thus predominantly used by the liver for blood-coagulating purposes. While sufficient for these purposes, the short half-life prevents the vitamin from being redistributed to extra-hepatic tissues in sufficient amounts. Vitamin K1 therefore is found to have very limited cardiovascular or bone health influence.
On the other hand, vitamin K2 MK-7's long (72-hour) half-life enables the vitamin to be distributed to extra-hepatic tissues, and thus affect cardiovascular and bone health.
For everybody, everywhere
The health and well-being demands of today's consumer are continually escalating - the quest for optimum childhood development and a longer, more active adulthood is a high priority. Yet, the incidence of negative bone conditions and cardiovascular diseases remains high, inhibiting optimum health across life.
The World Health Organization (WHO) cites that heart attacks and strokes represent 29% of all global deaths, making cardiovascular diseases one of the most prominent causes of early mortality.
After 30 years of age, bone mass decreases in men and women (osteoporosis). This affects one in three women and
one in five men globally with no discrimination based on geographical location.
Today's consumers are vitamin K2 MK-7 deficient and largely unaware of the vital role it can play in supporting an optimum healthy lifestyle. Hence, Kappa Bioscience's aim is to make vitamin K2 MK-7 available for everybody, everywhere to deliver the best possible bone-building and cardiovascular-health support, and minimise the risk of cardiovascular disease and early mortality.
The solution for bone and heart health
K2VITAL vitamin K2 MK-7 performs key health functions that are essential to optimal health:
- bone health: vitamin K2 MK-7 ensures calcium reaches the bone mass, assisting the bone-building process
- heart health: vitamin K2 MK-7 helps reduce the risk of arterial calcification, which can contribute to cardiovascular events and early mortality
- calcium balance: helps ensure calcium reaches where it is needed (the bone mass) and not on the arterial walls.
K2VITAL vitamin K2 MK-7 is a key vitamin for supporting the positive uptake of calcium when combined with vitamin D3.
This is called 'tri-essentials' - calcium, vitamin D3 and vitamin K2, working symbiotically to deliver the most optimal bone and heart health to consumers.
CBD vs CBG We like them both! GBG has been shown to boost available serotonin levels and by having an affinity for binding with CB2 receptors, it aids in and prolongs the effectiveness of CBD. We believe we've found the perfect ratio of these two powerhouse cannabinoids.We then use ultrasonic cavitation to mix the cannabinoids with organic olive oil and organic sunflower extract to make a 100% homogenous and highly bio available blend.
Ethanol plant extract
Organically grown approved hemp
Independently lab tested
Organic bio-available carrier oils
UK,USA and EU legal zero THC
Products containing cannabidiol (CBD) have exploded in popularity over the past few years, as the cannabinoid’s reputed anti-inflammatory and anti-oxidant effects have made it into a trendy ingredient for skincare brands and “wellness” products.
As the major non-intoxicating component in cannabis, CBD is fairly abundant in common cannabis strains, making the cannabinoid’s isolation and use easily translatable to product making operations.
CBG may sound similar to CBD on the surface, but dig a little deeper and key differences can be found.
What is CBG?
In the first two installments of this series on the chemistry of cannabis, CBDA Vs CBD: What Are the Differences? and THCA Vs THC: What Are the Differences?, it was explained how all of the cannabinoids present in cannabis are derived from cannabigerolic acid (CBGA).
Conversion of cannabigerolic acid (CBGA), into cannabigerol (CBG), and cannabidiol (CBD) via cannabidiolic acid (CBDA)
As the cannabis plant matures, CBGA, which is the acidic form of CBG, is converted by plant enzymes into some ratio of the three major cannabinoid precursors: tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), and cannabichromenic acid (CBCA).
From the amounts of CBGA that are not converted into these precursors, or any of the other minor cannabinoids, CBG is formed through decarboxylation.
Due to this process, cannabis strains ordinarily contain very little CBG, often below 1 percent by weight. In order to obtain higher yields of CBG within cannabis, specialist plant breeders have begun experimenting with genetic manipulation and crossbreeding. Leafly reports that scientists have also successfully pinpointed the optimum extraction window for cannabis in order to preserve the highest amounts of CBG, recommending extraction be done around six weeks into an eight-week flowering cycle.
Unlike CBD, which has a relatively low affinity for cannabinoid receptors and acts mostly through indirect interactions with the endocannabinoid system, CBG is thought to elicit its therapeutic effects directly though interaction with the CB1 and CB2 cannabinoid receptors in the brain.
The psychoactive cannabinoid THC also produces its psychoactive effects though interactions with these receptors; CBG has been observed to work as a buffer to THC’s psychoactivity and can even alleviate the feelings of paranoia that sometimes come with consumption of high levels of THC.
The difficulty producing CBG
With no intoxicating effects and a vast number of potential therapeutic uses, why hasn’t CBG experienced the same swell in popularity as CBD?
The largest stumbling block to CBG’s realization as a common therapeutic treatment is the cost of its production. CBG is thought to be one of the most expensive cannabinoids to produce, so much so that it has been dubbed “the Rolls-Royce of cannabinoids.”
“It takes thousands of pounds of biomass to create small amounts of CBG isolate,” James Rowland, CEO of the Colorado CBG brand Steve’s Goods, told Forbes.
“That’s because most hemp only contains minute percentages of CBG, whereas there are now hemp strains that contain 20 percent CBD in the crop. If the CBG content of the same crop is only 1 percent, that means you need to extract 20 times the amount of biomass to get the same amount of CBG out.”
CBG also presents a problem to cultivators. The longer that a cannabis plant matures, the more chance there is that the CBGA and CBG present in the strain will be converted into other cannabinoids. This leaves cultivators with a choice: either grow cannabis with the express purpose of producing CBG, meaning that you can harvest the crop early before this conversion completes; or allow the crop to fully mature, so that some of the crop can be sold for other purposes but the rest will have a lower CBG content for extraction.
As well as requiring larger amounts of plant material compared to THC or CBD extraction, CBG extraction also requires the use of specialized production equipment. Due to the low levels of CBG present in cannabis strains, the chromatography apparatus that is used to isolate and purify CBG extracts need to be as precise as possible, in order to not necessitate using even more raw cannabis or hemp material than is absolutely needed. The cost of this high-performance chromatography apparatus can be a high, up-front production cost for processors who may not already operate this equipment in their standard processing procedures.